



PST 2025

PROGRAM BOOK

The 8th International Conference and
Exhibition on Pharmaceutical Sciences
and Technology 2025
at Ambassador Hotel Bangkok, Thailand

"Advancing Pharmaceutical Frontiers: Collaboration,
Innovation, and Patient-Centric Solutions"

June 12 - 13, 2025



คณะเภสัชศาสตร์ มหาวิทยาลัยศิลปากร
FACULTY OF PHARMACY • SILPAKORN UNIVERSITY
LEARN TOGETHER, GROW TOGETHER

8th International Conference and Exhibition on Pharmaceutical Sciences and Technology (PST2025)

“Advancing Pharmaceutical Frontiers: Collaboration, Innovation, and Patient-Centric Solutions”

June 12-13, 2025

Ambassador Hotel Bangkok, Bangkok, Thailand

Organized by

Faculty of Pharmacy, Silpakorn University

Thai Industrial Pharmacist Association, Thailand

In association with

Faculty of Pharmaceutical Sciences, Burapha University, Thailand

Faculty of Pharmaceutical Sciences, Chulalongkorn University, Thailand

Faculty of Pharmaceutical Sciences, Huachiew Chalermprakiet University, Thailand

International Society for Pharmaceutical Engineering, Thailand Affiliate

Faculty of Pharmaceutical Sciences, Khon Kaen University, Thailand

Faculty of Pharmacy, Mahidol University, Thailand

Faculty of Pharmaceutical Sciences, Naresuan University, Thailand

Faculty of Pharmaceutical Sciences, Prince of Songkla University, Thailand

College of Pharmacy, Rangsit University, Thailand

Faculty of Pharmacy, Siam University, Thailand

Faculty of Pharmacy, Silpakorn University, Thailand

Faculty of Pharmacy, Srinakharinwirot University, Thailand

Faculty of Pharmacy, Thammasat University, Thailand

Faculty of Pharmaceutical Sciences, Ubon Ratchathani University, Thailand

School of Pharmaceutical Sciences, University of Phayao, Thailand

School of Pharmacy, Walailak University, Thailand

Council of Pharmacy Deans of Thailand



ISPE®

Thailand
Affiliate



CPD² COUNCIL OF
PHARMACY DEANS
OF THAILAND

Table of Contents

About PST2025.....	3
Welcome Message from the Dean of Faculty of Pharmacy, Silpakorn University.....	4
Welcome Message from TIPA.....	5
Host Institutions.....	6
Advisory Board.....	7
Organizing Committee	9
Scientific Committees.....	11
Sponsors/ Acknowledgement.....	18
SCIENTIFIC PROGRAM.....	20
DAY 1 : 12 June 2025.....	20
DAY 2 : 13 June 2025.....	21
List of Invited Speakers.....	22
ABSTRACTS - SPEAKERS.....	24
IS-01.....	25
IS-02.....	26
IS-03.....	27
IS-04.....	28
IS-05.....	29
IS-06.....	30
IS-07.....	31
IS-08.....	32
Venue.....	33
Sponsors/ Acknowledgement.....	34

About PST2025

The 8th International Conference and Exhibition on Pharmaceutical Sciences and Technology is an annual academic event organized by educational institutions and professional associations within Thailand. Scheduled for June 12th - 13th, 2025, Ambassador Hotel in Bangkok, Thailand, the PST 2025 Conference serves as a hub for researchers, scholars, students, and practitioners across diverse disciplines to exchange ideas, deliberate on recent trends, and showcase their research within the pharmaceutical sciences and related fields.

Theme:

Under the overarching theme, “Advancing Pharmaceutical Frontiers: Collaboration, Innovation, and Patient-Centric Solutions” this year's conference will delve into the latest breakthroughs and challenges in pharmaceutical science and technology. The exploration will extend its influence into numerous fields, including pharmaceuticals, industrial pharmacy, pharmaceutical manufacturing, pharmaceutical engineering, pharmacognosy, pharmaceutical analysis, medicinal chemistry, pharmacology, toxicology, cosmetic sciences, biotechnology, nanotechnology, nutraceuticals, and other related fields.

Conference Highlights:

The conference program encompasses keynote lectures, oral presentations, poster presentations, and exhibitions, all addressing topics in alignment with the conference theme. It offers an outstanding platform for participants to establish connections, foster collaborations, and gain insights from diverse experiences and viewpoints. The picturesque setting of Bangkok, renowned for its natural splendor and cultural heritage, enhances the conference's distinctive ambiance.

Celebrating 40 Years of Excellence: Join Us at Our Anniversary Conference!

We are thrilled to announce a momentous milestone in our Faculty of Pharmacy Silpakorn University journey – our 40th anniversary. To mark this significant occasion, we invite you to join us in celebrating our legacy of innovation, professional growth, and collaboration. We extend a cordial invitation to scholars, researchers, practitioners, and students to submit their research papers and actively engage in this exceptional event. For any inquiries or assistance, please do not hesitate to reach out to us at secretary.pst2025@su.ac.th. Thank you for being an essential part of our 40-year journey, and we look forward to celebrating together.



Message from PST2025 Conference Chairman / Dean of Faculty of Pharmacy, Silpakorn University

Dear Colleagues, Researchers, and Healthcare Professionals,

It is my great pleasure to welcome you to the 8th International Conference and Exhibition on Pharmaceutical Sciences and Technology (PST 2025), held on June 12–13, 2025, at the Ambassador Hotel, Bangkok, Thailand.

Under the theme “Advancing Pharmaceutical Frontiers: Collaboration, Innovation, and Patient-Centric Solutions,” PST 2025 aims to provide a vibrant platform for knowledge exchange and partnership across academia, industry, and healthcare. In an era of rapid transformation, this conference offers a timely opportunity to explore emerging trends, share cutting-edge research, and inspire impactful practices in pharmaceutical sciences.

The program features keynote lectures, scientific presentations, workshops, and exhibitions that reflect the dynamic needs of the profession. Through these sessions, we hope to spark innovation, encourage collaboration, and foster meaningful dialogue among participants from around the globe.

I would like to express my deepest appreciation to the Faculty of Pharmacy, Silpakorn University, our co-hosting institutions, professional partners, and sponsors for their generous support and unwavering commitment to the success of this event.

We are delighted to have you here in Bangkok for this unforgettable experience of learning, networking, and advancing health through science.



Warm regards,

A handwritten signature in blue ink, consisting of stylized, overlapping loops and a final vertical stroke.

Professor Pornsak Srimornsak, PhD, FCIP, FACP, AFRST
Conference Chairman, PST 2025

Welcome Message from TIPA

Dear Colleagues and Friends,

On behalf of the Thai Industrial Pharmacist Association (TIPA), it is our pleasure and honor to welcome all of you here in Bangkok for the 8th International Conference and Exhibition on Pharmaceutical Sciences and Technology (PST2025). We are thrilled to host you at the Ambassador Hotel from June 12th to 13th, 2025.

Our theme this year, "Advancing Pharmaceutical Frontiers: Collaboration, Innovation, and Patient-Centric Solutions," truly reflects the dynamic and vital mission of our profession. In an era of evolving scientific discovery and fast growing global health needs, the pharmaceutical landscape demands innovation, collaboration, and unwavering patient-centric mindsets.

PST2025 brings together top-notch experts, researchers, industry professionals, and brilliant aspiring minds from across the globe. Over the next two days, you will have the invaluable opportunity to engage in insightful discussions, discover cutting-edge research findings, and witness the latest technological innovations that are actively shaping the future of pharmaceutical sciences and technology.

Apart from discovering insights, innovations, and opportunities within our field, I sincerely hope you will also take some time to experience the vibrant culture and renowned hospitality that Bangkok so warmly offers.


Thank you for your presence and your invaluable contributions to PST2025. Your active participation makes this conference a truly enriching and memorable experience for all.

Wishing you a most productive, inspiring, and engaging conference!

Sincerely,



Warm regards,



Rungnapa Amarinthnukrowh

President, Thai Industrial Pharmacist Association

Host Institutions

Faculty of Pharmacy, Silpakorn University
Thai Industrial Pharmacist Association, Thailand

Co-Host Institutions

Faculty of Pharmaceutical Sciences, Burapha University, Thailand
Faculty of Pharmaceutical Sciences, Chulalongkorn University, Thailand
Faculty of Pharmaceutical Sciences, Huachiew Chalermprakiet University, Thailand
International Society for Pharmaceutical Engineering, Thailand Affiliate
Faculty of Pharmaceutical Sciences, Khon Kaen University, Thailand
Faculty of Pharmacy, Mahidol University, Thailand
Faculty of Pharmaceutical Sciences, Naresuan University, Thailand
Faculty of Pharmaceutical Sciences, Prince of Songkla University, Thailand
College of Pharmacy, Rangsit University, Thailand
Faculty of Pharmacy, Siam University, Thailand
Faculty of Pharmacy, Silpakorn University, Thailand
Faculty of Pharmacy, Srinakharinwirot University, Thailand
Faculty of Pharmacy, Thammasat University, Thailand
Faculty of Pharmaceutical Sciences, Ubon Ratchathani University, Thailand
School of Pharmaceutical Sciences, University of Phayao, Thailand
School of Pharmacy, Walailak University, Thailand
Council of Pharmacy Deans of Thailand

Publication Partners

Natural and Life Sciences Communications (NLSC)

<https://cmuj.cmu.ac.th/nlsc/>

Science, Engineering and Health Studies (SEHS)

<https://li01.tci-thaijo.org/index.php/sehs>

Pharmaceutical Sciences Asia (PSA)

<https://li04.tci-thaijo.org/index.php/PSA>

Advisory Board

Prof. Dr. Chomchin Chantaraskul	Advisory Board of Thai Industrial Pharmacist Association (TIPA), Thailand
Dr. Sorada Wangmethukul	Advisory Board of Thai Industrial Pharmacist Association (TIPA), Thailand
Ms. Rungnapa Amarinthnukrowh	President of Thai Industrial Pharmacist Association (TIPA), Thailand
Mr. Totsapon Santitewagun	President of International Society for Pharmaceutical Engineering (ISPE), Thailand
Prof. Dr. Pornsak Sriamornsak	Dean of Faculty of Pharmacy Silpakorn University, Thailand
Assoc. Prof. Dr. Vorasit Vongsutilers	Dean, Faculty of Pharmaceutical Sciences, Chulalongkorn University
Asst. Prof. Dr. Narin Chansri	Dean of Faculty of Pharmaceutical Sciences, Khon Kaen University, Thailand
Prof of Practice Dr. Supat Jiranusornkul	Dean of Faculty of Pharmacy, Chiang Mai University, Thailand
Assoc. Prof. Dr. Arom Jedsadayanmata	Dean of Faculty of Pharmacy Thammasat University, Thailand
Assoc. Prof. Dr.Rattima Jeenapongsa	Dean of Faculty of Pharmaceutical Sciences, Naresuan University, Thailand
Dr. Nuttinee Teerakulkittipong	Dean of Faculty of Pharmaceutical Sciences, Burapha University, Thailand
Assoc. Prof. Dr. Surasak Saokaew	Dean of Faculty of Pharmaceutical Sciences, University of Phayao, Thailand
Assoc. Prof. Surakit Nathisuwan	Dean of Faculty of Pharmacy, Mahidol University, Thailand
Asst. Prof. Dr. Wimon Phuntuwate	Dean of Faculty of Pharmacy Srinakharinwirot University, Thailand

Assoc. Prof. Dr. Nimit Worakul

Dean of Faculty of Pharmaceutical Sciences,
Prince of Songkla University, Thailand

Dr. Ruxjinda Wattanalai

Acting Dean of Faculty of Pharmacy
Siam University, Thailand

Dr. Hansa Mahamongkol

Dean of Faculty of Pharmaceutical Sciences,
Huachiew chalermprakiet University, Thailand

Dr. Saksit Sripa

Dean of Faculty of Pharmaceutical Sciences,
Ubon Ratchathani University, Thailand

Asst. Prof. Dr. Thanapat Songsak

Dean of Collage of Pharmacy
Rangsit University, Thailand

Dr. Jiraporn Chingunpitak

Dean of School of Pharmacy
Walailak University, Thailand



Organizing Committee

Ms. Wannee Panitphong	Thai Industrial Pharmacist Association (TIPA), Thailand
Mr. Atit Sodsangaroonngam	Thai Industrial Pharmacist Association (TIPA), Thailand
Mr. Totsapon Santitewagun	International Society for Pharmaceutical Engineering (ISPE), Thailand
Dr. Sasivimol Kittivoravitkul	International Society for Pharmaceutical Engineering (ISPE), Thailand
Prof. Dr. Pornsak Sriamornsak	Faculty of Pharmacy, Silpakorn University, Thailand
Prof. Dr.Sontaya Limmatvampirat	Faculty of Pharmacy, Silpakorn University, Thailand
Assoc. Prof. Dr. Suchada Piriyaprasarth	Faculty of Pharmacy, Silpakorn University, Thailand
Assoc. Prof. Dr. Prasopchai Patrojanasophon	Faculty of Pharmacy, Silpakorn University, Thailand
Assoc. Prof. Dr. Nattawat Nattapulwat	Faculty of Pharmacy, Silpakorn University, Thailand
Asst. Prof. Dr. Amornrat Chaidedgumjorn	Faculty of Pharmacy, Silpakorn University, Thailand
Asst. Prof. Dr. Tossawan Jitwasinkul	Faculty of Pharmacy, Silpakorn University, Thailand
Dr. Waraporn Soksawatmaekhin	Faculty of Pharmacy, Silpakorn University, Thailand
Dr. Prin Chaksmithanont	Faculty of Pharmacy, Silpakorn University, Thailand
Dr. Thapakorn Charoenying	Faculty of Pharmacy, Silpakorn University, Thailand
Asst. Prof. Dr. Suang Rungpragayphan	Faculty of Pharmacy, Silpakorn University, Thailand
Asst. Prof. Dr. Chaiyakarn Pornpitchanarong	Faculty of Pharmacy, Silpakorn University, Thailand
Asst. Prof. Dr. Tosak Intaraphairot	Faculty of Pharmacy, Silpakorn University, Thailand

Asst. Prof. Dr. Narueporn Sutanthavibul	Faculty of Pharmaceutical Sciences, Chulalongkorn University
Asst. Prof. Dr. Pathomthat Srisuk	Faculty of Pharmaceutical Sciences, Khon Kaen University, Thailand
Dr. Angsuma Phongphisutthinan	Faculty of Pharmacy, Thammasat University, Thailand
Assoc. Prof. Dr. Chuda Chittasupho	Faculty of Pharmacy, Chiang Mai University, Thailand
Asst. Prof. Dr. Sasiprapa Limsirilak	Faculty of Pharmaceutical Sciences, Naresuan University, Thailand
Assoc. Prof. Dr. Supang Khondee	School of Pharmaceutical Sciences, Phayao University, Thailand
Asst. Prof. Dr. Wichit Nosoongnoen	Faculty of Pharmacy, Mahidol University, Thailand
Dr. Duangratana Shuwisitkul	Faculty of Pharmacy, Srinakharinwirot University, Thailand
Asst. Prof. Dr. Chatchai Wattanapiromsakul	Faculty of Pharmaceutical Sciences, Prince of Songkla University, Thailand
Dr. Phennapa Charoenwiwattanakij	Faculty of Pharmacy, Siam University, Thailand
Dr. Chirattikan Maicheen	Faculty of Pharmaceutical Sciences, Huachiew Chalermprakiet University
Asst. Prof. Dr. Thaweesak Juengwatanatrakul	Faculty of Pharmaceutical Sciences, Ubon Ratchathani University, Thailand
Assoc. Prof. Dr. Kampanart Huanbutta	College of Pharmacy, Rangsit University, Thailand
Assoc. Prof. Dr. Boonyadist Vongsak	Faculty of Pharmaceutical Sciences, Burapha University, Thailand
Dr. Bhudsaban Sukkarn	School of Pharmacy, Walailak University, Thailand

Scientific Committees

Prof. Crispin R Dass	Curtin University, Australia
Prof. Wong Tin Wui	Universiti Teknologi Mara, Malaysia
Prof. Bhupendra G. Prajapati	Ganpat University, India
Prof. Dr. Hirofumi Takeuchi	Gifu Pharmaceutical University, Japan
Prof. Dr. Mitsuhiro Nakamura	Gifu Pharmaceutical University, Japan
Dr. Pitsiree Praphanwittaya	Landspítali University Hospital, Iceland
Dr.rer.nat. apt. Nanang Fakhruddin	Gadjah Mada University, Indonesia
Dr.rer.nat. Maria Lucia Ardhani Dwi Lestari	Universitas Airlangga, Indonesia
Asst. Prof. Ichwan Ridwan Rais	Ahmad Dahlan University, Indonesia
Dr. Marlyn Dian Laksitorini	University of Gadjah Mada, Indonesia
Prof. Eliana B. Souto	University College Dublin, Ireland
Prof. Elka Touitou	Hebrew University of Jerusalem, Israel
Prof. Dr. Yoshihiro Hayakawa	University of Toyama, Toyama, Japan
Prof. Hitoshi Sato	Showa University, Japan
Asst. Prof. Dr. Ryusho Kariya	Kobe Gakuin University, Japan
Assoc. Prof. Dr. Seiichi Sakamoto	Kyushu University, Japan
Assoc. Prof. Dr. Shinichi Fujiwara	Tottori University, Japan
Prof.Yutaka Inoue	Josai University, Japan
Dr.Nicholas M.H. Khong	Monash University, Malaysia
Dr.Choon Fu Goh	Universiti Sains, Malaysia
Junnasir M. Sakilan	Jose Rizal Memorial State University, Philippines
Jhoan Rhea L. Pizon	Jose Rizal Memorial State University, Philippines
Assoc. Prof. Dr. Ana Rita C. Duarte	University of Nova Lisboa, Portugal
Assoc. Prof. Dr. Maria Helena Amaral	University of Porto, Portugal
Prof. Dr. Baek Seung Joon	Seoul National University, South Korea
Prof. Dr. Isik Ozguney	Ege University, Türkiye

Dr. Kumar Paul	University of Nebraska–Lincoln, USA
Dr. Pham Duy Toan	Can Tho University, Vietnam
Prof. Dr. Sontaya Limmatvapirat	Faculty of Pharmacy, Silpakorn University, Thailand
Prof. Dr. Praneet Opanasopit	Faculty of Pharmacy, Silpakorn University, Thailand
Prof. Dr. Thawatchai Phaechamud	Faculty of Pharmacy, Silpakorn University, Thailand
Assoc.Prof. Dr. Suchada Piriyaprasarth	Faculty of Pharmacy, Silpakorn University, Thailand
Assoc.Prof. Dr. Chutima Limmatvapirat	Faculty of Pharmacy, Silpakorn University, Thailand
Assoc.Prof. Dr. Chatchai Chinpaisal	Faculty of Pharmacy, Silpakorn University, Thailand
Assoc.Prof. Dr. Theerasak Rohanarata	Faculty of Pharmacy, Silpakorn University, Thailand
Assoc.Prof. Dr. Prasopchai Patrojanasophon	Faculty of Pharmacy, Silpakorn University, Thailand
Asst.Prof. Dr. Pawaris Wongprayoon	Faculty of Pharmacy, Silpakorn University, Thailand
Asst.Prof. Dr. Purin Charoensuksai	Faculty of Pharmacy, Silpakorn University, Thailand
Asst.Prof. Dr. Supusson Pengnam	Faculty of Pharmacy, Silpakorn University, Thailand
Asst.Prof. Dr. Chaiyakarn Pornpitchanarong	Faculty of Pharmacy, Silpakorn University, Thailand
Assoc. Prof. Dr. Malai Satiraphan	Faculty of Pharmacy, Silpakorn University, Thailand

Assoc. Prof. Dr. Panadda Phattanawasin	Faculty of Pharmacy, Silpakorn University, Thailand
Assoc. Prof. Dr. Uthai Sotanaphun	Faculty of Pharmacy, Silpakorn University, Thailand
Prof. Pithi Chanvorachote	Faculty of Pharmaceutical Sciences, Chulalongkorn University, Thailand
Assoc.Prof. Dr. Bodin Tuesuwan	Faculty of Pharmaceutical Sciences, Chulalongkorn University, Thailand
Asst. Prof. Dr. Jittima Chatchawalsaisin	Faculty of Pharmaceutical Sciences, Chulalongkorn University, Thailand
Assoc. Prof. Dr. Varin Titapiwatanakun	Faculty of Pharmaceutical Sciences, Chulalongkorn University, Thailand
Assoc. Prof. Dr. Chaisak Chansriniyom	Faculty of Pharmaceutical Sciences, Chulalongkorn University, Thailand
Assoc. Prof. Dr. Weerachai Chaijamorn	Faculty of Pharmaceutical Sciences, Chulalongkorn University, Thailand
Asst.Prof. Dr. Pathomthat Srisuk	Faculty of Pharmaceutical Sciences, Khon Kaen University, Thailand
Assoc. Prof. Dr. Napaphak Jaipakdee	Faculty of Pharmaceutical Sciences, Khon Kaen University, Thailand
Assoc. Prof. Dr. Watcharee Khunkitti	Faculty of Pharmaceutical Sciences, Khon Kaen University, Thailand
Assoc. Prof. Dr. Khaetthareeya Sutthanut	Faculty of Pharmaceutical Sciences, Khon Kaen University, Thailand
Assoc. Prof. Dr. Chantana Boonyarat	Faculty of Pharmaceutical Sciences, Khon Kaen University, Thailand
Assoc.Prof. Dr. Pakorn Kraisit	Faculty of Pharmacy, Thammasat University, Thailand

Assoc. Prof. Dr. Sewan Theeramunkong	Faculty of Pharmacy, Thammasat University, Thailand
Dr. Nipawan Nuemket	Faculty of Pharmacy, Thammasat University, Thailand
Dr. Angsuma Phongphisutthinan	Faculty of Pharmacy, Thammasat University, Thailand
Dr. Suphattra Sangmalee	Faculty of Pharmacy, Thammasat University, Thailand
Asst.Prof. Dr. Phennapha Saokham	Faculty of Pharmacy, Chiang Mai University, Thailand
Assoc.Prof. Dr.Chuda Chittasupho	Faculty of Pharmacy, Chiang Mai University, Thailand
Asst. Prof. Dr. Aekkhakuck Intharuksa	Faculty of Pharmacy, Chiang Mai University, Thailand
Asst. Prof. Dr. Mathukorn Sainakham	Faculty of Pharmacy, Chiang Mai University, Thailand
Asst. Prof. Dr. Pratchaya Tipduangta	Faculty of Pharmacy, Chiang Mai University, Thailand
Dr. Karnkamol Trisopon	Faculty of Pharmacy, Chiang Mai University, Thailand
Asst.Prof. Dr. Worawut Kiangkrai	Faculty of Pharmaceutical Sciences, Naresuan University, Thailand
Asst.Prof. Dr. Sukannika Tubtimsri	Faculty of Pharmaceutical Sciences, Burapha University, Thailand
Assoc.Prof. Boonyadist Vongsak	Faculty of Pharmaceutical Sciences, Burapha University, Thailand
Assoc.Prof. Samarwadee Plianwong	Faculty of Pharmaceutical Sciences, Burapha University, Thailand
Asst.Prof. Pattaravadee Srikoorn	Faculty of Pharmaceutical Sciences, Burapha University, Thailand
Asst.Prof. Dr. Nuttakorn Baisaeng	School of Pharmaceutical Sciences, University of Phayao, Thailand

Assist. Prof. Dr. Supavadee Boontha	School of Pharmaceutical Sciences, University of Phayao, Thailand
Assoc. Prof. Dr. Supang Khondee	School of Pharmaceutical Sciences, University of Phayao, Thailand
Dr. Suthida Boonsom	School of Pharmaceutical Sciences, University of Phayao, Thailand
Assoc.Prof. Dr. Nantana Nuchtavorn	Faculty of Pharmacy, Mahidol University, Thailand
Assoc.Prof. Dr. Piyanuch Rojsanga	Faculty of Pharmacy, Mahidol University, Thailand
Assoc. Prof. Dr. Savita Chewchinda	Faculty of Pharmacy, Mahidol University, Thailand
Assoc. Prof. Dr. Doungdaw Chantasart	Faculty of Pharmacy, Mahidol University, Thailand
Asst.Prof. Dr. Sujimon Tunvichien	Faculty of Pharmacy, Srinakharinwirot University, Thailand
Assist. Prof. Boonta Chutvirasakul	Faculty of Pharmacy, Srinakharinwirot University, Thailand
Assist. Prof. Chutwadee Krisanapun	Faculty of Pharmacy, Srinakharinwirot University, Thailand
Assoc. Prof. Worapan Sitthithaworn	Faculty of Pharmacy, Srinakharinwirot University, Thailand
Assoc. Prof. Dr.Wiwat Pichayakorn	Faculty of Pharmaceutical Sciences, Prince of Songkla University, Thailand
Assoc. Prof. Luelak Lomlim	Faculty of Pharmaceutical Sciences, Prince of Songkla University, Thailand
Assoc. Prof. Supinya Tewtrakul	Faculty of Pharmaceutical Sciences, Prince of Songkla University, Thailand
Prof. Teerapol Srichana	Faculty of Pharmaceutical Sciences, Prince of Songkla University, Thailand
Assoc. Prof. Prapaporn Boonme	Faculty of Pharmaceutical Sciences, Prince of Songkla University, Thailand

Dr. Chutimon Muankaew	Faculty of Pharmacy, Siam University, Thailand
Asst. Prof. Dr. Noppadol Chongcherdsak	Faculty of Pharmacy, Siam University, Thailand
Asst. Prof. Dr. Narumol Phosrithong	Faculty of Pharmacy, Siam University, Thailand
Dr. Phennapa Charoenwiwattanakij	Faculty of Pharmacy, Siam University, Thailand
Asst.Prof. Dr. Chawalinee Asawahame	Faculty of Pharmaceutical Sciences, Huachiew Chalermprakiet University, Thailand
Dr. Kritsanaporn Tansathien	Faculty of Pharmaceutical Sciences, Huachiew Chalermprakiet University, Thailand
Dr. Ratana Indranupakorn	Faculty of Pharmaceutical Sciences, Huachiew Chalermprakiet University, Thailand
Dr. Sarawuth Phosri	Faculty of Pharmaceutical Sciences, Huachiew Chalermprakiet University, Thailand
Dr. Chirattikan Maicheen	Faculty of Pharmaceutical Sciences, Huachiew Chalermprakiet University, Thailand
Assoc.Prof. Dr. Sureewan Duangjit	Faculty of Pharmaceutical Sciences, Ubon Ratchathani University, Thailand
Assoc. Prof. Dr. Pornthip Waiwut	Faculty of Pharmaceutical Sciences, Ubon Ratchathani University, Thailand
Asst. Prof. Dr. Kusuma Jitsaeng	Faculty of Pharmaceutical Sciences, Ubon Ratchathani University, Thailand
Kasitpong Thanawuth	College of Pharmacy, Rangsit University, Thailand

Dr. Bhudsaban Sukkarn

School of Pharmacy, Walailak University,
Thailand

Assoc. Prof. Dr. Wandee Rungseevijitprapa

School of Cosmetic Science, Mae Fah Luang
University, Thailand





MAXWAY
COMPANY LIMITED

YOUR FORMULATION PARTNER



Please contact us if you have a plan to develop new formulations

We offer a wide range of pharma excipients; Diluent | Binders | Disintegrants | Lubricants
| Moisture absorbents | Viscosity modifiers | Taste masking agents | Controlled-release agents
| Film coating agents | Surfactants | Minerals | Flavors | Colors and etc.

335/47 Srinakarin Road Nongbon Prayet Bangkok 10250



Tel: 02-3660263-7



info@maxway.in.th



Fax: 02-3660729



www.maxway.co.th

• Manufactures & Sales from JBKLAB

Start now CellMed®

Meet your personalized 1:1 health functional food
at the pharmacy's health functional food corner

- Personalized health functional food service
regulatory exception company in Korea -



CellMed, combined with nature and science, is a nutrition brand
dedicated to the health functional food at the pharmacy for a healthy life.

Health functional food

SCIENTIFIC PROGRAM

DAY 1 : 12 June 2025

Time	Activities
08.15-09.00	Registration
09.00-09.15	Welcome Remark & Opening Ceremony
09.15-10.00	Plenary Lecture I: Prof. Crispin R Dass “Search for novel bioactives against cancer: focus on PEDF”
10.00-10.20	Coffee break and poster viewing
10.20-11.05	Plenary Lecture II: Prof. Hirofumi Takeuchi “Challenges in Pharmaceutical technology for patient centric drug therapy”
11.10-11.45	Industrial talk: Eirich Thailand
11.45-12.45	Lunch
12.45 – 13.05	Poster viewing and presentation
13.05-14.50	Oral presentation
14.50-15.10	Coffee break, Exhibition, Poster viewing and Presentation
15.10-16.35	Oral presentation

DAY 2 : 13 June 2025

Time	Activities
08.30-09.00	Registration
09.00-09.45	Plenary Lecture III: Prof. Wong Tin Wui “Cancer nanomedicine development: Bench innovation to clinical translation”
09.50-10.35	Plenary Lecture IV: Prof. Pithi Chanvorachote “Signaling the Future: Unlocking Innovation Through Skin Stem Cell Pathways”
10.35-11.00	Coffee break, Exhibition, Poster viewing and presentation
11.00-11.45	Plenary Lecture V: Prof. Mitsuhiro Nakamura “Comparative Analysis of Adverse Event Profiles Across Drug Dosage Forms Using Real-World Data”
11.45-12.45	Lunch and Exhibition
12.45-13.15	Poster viewing and presentation
13.15-14.00	Plenary Lecture VI: Dr. Hiroyuki Kojima (Astellas Pharma Inc.) “History and Next Era of Pharmaceutical Drug Development from Industrial Perspective”
14.05-14.50	Plenary Lecture VII: Prof. Bhupendra G. Prajapati “Lipid-Based Novel Formulations for Effective Ocular Drug Delivery”
14.50-15.05	Coffee break, Exhibition, and Poster viewing
15.05-15.50	Plenary Lecture VIII: Prof. Soyoung Shin “Advancing the development of GLP-1 receptor agonist: PK/PD considerations”
15.50-16.15	Awarding & Closing ceremony

List of Invited Speakers

	12 June 2025 09.15–10.00	<i>Invited Speakers 1 (IS-01)</i> “Search for novel bioactives against cancer: focus on PEDF” Prof. Crispin R Dass Director Graduate Research - Curtin Medical School, Curtin University, Australia
	12 June 2025 10.20–11.05	<i>Invited Speakers 2 (IS-02)</i> “Challenges in Pharmaceutical technology for patient centric drug therapy” Prof. Hirofumi Takeuchi Advanced Pharmaceutical Process Engineering, Gifu Pharmaceutical University, Japan
	13 June 2025 09.00–09.45	<i>Invited Speakers 3 (IS-03)</i> “Cancer nanomedicine development: Bench innovation to clinical translation” Prof. Wong Tin Wui Universiti Teknologi Mara, Malaysia
	13 June 2025 09.50–10.35	<i>Invited Speakers 4 (IS-04)</i> "Signaling the Future: Unlocking Innovation Through Skin Stem Cell Pathways" Prof. Pithi Chanvorachote Department of Pharmacology and Physiology, Faculty of Pharmaceutical Sciences, Chulalongkorn University

	13 June 2025 11.00–11.45	<i>Invited Speakers 5 (IS-05)</i> “Comparative Analysis of Adverse Event Profiles Across Drug Dosage Forms Using Real-World Data” Prof. Mitsuhiro Nakamura Laboratory of Drug Informatics, Gifu Pharmaceutical University, Japan
	13 June 2025 13.15–14.00	<i>Invited Speakers 6 (IS-06)</i> “History and Next Era of Pharmaceutical Drug Development from Industrial Perspective” Dr. Hiroyuki Kojima Senior Vice President, Head of Pharmaceutical Research & Technology Labs, Astellas Pharma Inc., Japan.
	13 June 2025 14.05–14.50	<i>Invited Speakers 7 (IS-07)</i> “Lipid-Based Novel Formulations for Effective Ocular Drug Delivery” Prof. Bhupendra G. Prajapati College of Pharmaceutical Education and Research, Ganpat University India
	13 June 2025 15.05–15.50	<i>Invited Speakers 8 (IS-08)</i> “Advancing the development of GLP-1 receptor agonist: PK/PD considerations” Prof. Soyoung Shin College of Pharmacy, Chung-Ang University

ABSTRACTS - SPEAKERS

(IS-01)

Search for novel bioactives against cancer: focus on PEDF

¹Crispin R. Dass*

¹ Director Graduate Research - Curtin Medical School, Curtin University, Australia

* Corresponding author Email: crispin.dass@curtin.edu.au

ABSTRACT

Cancer and diabetes are two major killers in modern society, increasing in incidence in developing nations due to a variety of reasons, change of diet and lifestyle being a big factor. Pigment epithelium-derived protein (PEDF) is linked to various biological/physiological processes, and its absence or dysfunction can lead to a variety of ailments such as cancer and diabetes. It is also considered a biomarker for certain metabolic syndromes, which include cancer and diabetes. Starting from our early work in 2005 in linking PEDF to the devastating bone cancer osteosarcoma, we have travelled 20 years to the role PEDF plays in insulin resistance and diabetes, and design and testing of short peptides based off the parent PEDF sequence as we slowly move towards clinical trials. PEDF is also a potent bone regeneration protein, able to stimulate stem cells to form bone when implanted in muscle or adipose tissue in vivo. Some of these data will be discussed. Drawing on past success of hosting Thai students at Curtin University, opportunities for collaborations and student exchange will also be presented briefly.

Challenges in Pharmaceutical technology for patient centric drug therapy

¹Hirofumi Takeuchi*

¹ Advanced Pharmaceutical Process Engineering, Gifu Pharmaceutical University, Japan

* Corresponding author E-mail: takeuchi@gifu-pu.ac.jp

ABSTRACT

Patient centric is one of the most important key words in recent drug therapy. In developing dosage forms, pharmaceuticals researchers try to find a suitable administration route with a dosage form to reach the most effective and safe drug delivery. In considering patient centricity in drug therapy, easy administration with higher adhesiveness to drug administration is also an important factor in designing the dosage forms.

In this presentation the trends and challenges for developing patient centric dosage forms are introduced in the following 4 points.

1. Development of several dosage forms considering the types of patients or diseases
2. New dosage form designs for pediatric and geriatric patients: ODT and ODF
3. Other topics in drug administration
4. Colloidal drug delivery for the better drug administration: Eye drops for drug delivery to retina

After introducing some commercially developed dosage forms for considering patient use, information about orally disintegrating tablets (ODTs) and films (ODFs) are explained as typical patient centric oral dosage forms (1 and 2). The drugs for COVID-19 are included in this part. In the point 3, I would like to briefly talk about i) IoT for drug administration and health (IoMT) ii) development of pediatric drug (dosage forms) iii) tube administration of oral dosage forms.

In changing the administration method, new technology is sometimes required. Novel technology on colloidal particles is one of the useful tools to design the dosage form. In the point 4, I would like to introduce our results about delivery of drug to the posterior part of the eye (retina) by using liposomes.

Cancer nanomedicine development: Bench innovation to clinical translation

^{1,2,3} Wong Tin Wui*

¹ Non-Destructive Biomedical and Pharmaceutical Research Centre, Smart Manufacturing Research Institute, Universiti Teknologi MARA Selangor, Puncak Alam 42300, Selangor, Malaysia

² Particle Design Research Group, Faculty of Pharmacy, Universiti Teknologi MARA Selangor, Puncak Alam 42300, Selangor, Malaysia

³ Department of Industrial Pharmacy, Faculty of Pharmacy, Silpakorn University, Nakhon Pathom, 73000, Thailand

* Corresponding author E-mail: wongtinwui@uitm.edu.my

ABSTRACT

The personalised perspective of precision medicine in cancer therapy involves patient's health/omics analysis and therapy customized to the individual health requirements. More than one drug may be delivered in variable doses, in specific delivery kinetics, and to different intended target sites of action. An ideal dosage form is preferably can be dispensed flexibly with the required drug delivery characteristics. The dosage form should ideally be characterized by 100 % drug bioavailability. This presentation highlights the recent nano cancer drug delivery innovations for skin, pulmonary and oral applications from the perspectives of material design, processing technology, dosage form development, and active device invention to realize the true meaning of personalized therapy. Excipient selection for precision cancer nanomedicine development against the profiles of cancer cell target and metabolizing enzyme will be discussed from the perspective of cancer omics/healthcare analysis.

Signaling the Future: Unlocking Innovation Through Skin Stem Cell Pathways

¹Pithi Chanvorachote*

¹ Department of Pharmacology and Physiology, Faculty of Pharmaceutical Sciences, Chulalongkorn University, Bangkok, Thailand.

* Corresponding author E-mail: pithi.c@chula.ac.th

ABSTRACT

Skin stem cells are essential for the maintenance, repair, and regeneration of the epidermis, serving as a critical bridge between fundamental biological research and translational medical applications. *"Signaling the Future: Unlocking Innovation Through Skin Stem Cell Pathways"* examines the intricate signaling networks—such as Wnt, Notch, Hedgehog, and BMP—that orchestrate skin stem cell behavior under both physiological and pathological conditions. In contrast, cellular senescence—long regarded as a hallmark of aging—is now recognized for its complex, dual role in stem cell regulation: acting both as an impediment to regeneration and as a modulator of tissue remodeling. This presentation explores the dynamic interplay between senescence-associated signaling and stem cell function, and how it shapes skin homeostasis, aging, and the tissue's response to injury. We further discuss how these insights are informing the development of next-generation therapies, including pro-regenerative strategies and senolytic interventions. By integrating advances in stem cell signaling with emerging knowledge of senescence, this work highlights the transformative potential of targeting these pathways to unlock new frontiers in regenerative medicine and therapeutic innovation.

(IS-05)

Comparative Analysis of Adverse Event Profiles Across Drug Dosage Forms Using Real-World Data

¹Mitsuhiro Nakamura*

¹ Laboratory of Drug Informatics, Gifu Pharmaceutical University, Japan

* Corresponding author E-mail: mnakamura@gifu-pu.ac.jp

ABSTRACT

In this presentation, we will introduce a series of retrospective studies conducted using spontaneous reporting system (SRS) databases to evaluate drug-associated adverse events. The studies include:

- (1) An analysis of drug-induced gingival hyperplasia based on data from the Japanese Adverse Drug Event Report database (JADER);
- (2) A comparison of adverse event profiles between conventional and liposomal formulations of doxorubicin using the FDA Adverse Event Reporting System (FAERS);
- (3) An investigation into chemotherapy-induced peripheral neuropathy associated with solvent-based paclitaxel and nanoparticle albumin-bound paclitaxel using JADER; and
- (4) A comparison of adverse event profiles of different formulations of amphotericin B using real-world data from FAERS.

These studies demonstrate the utility of SRS databases in pharmacovigilance and provide insights into formulation-specific safety profiles of commonly used medications.

(IS-06)

History and Next Era of Pharmaceutical Drug Development from Industrial Perspective

^{1,2,3,4}Hiroyuki Kojima*

¹ Senior Vice President, Head of Pharmaceutical Research and Technology Labs, CMC-Development, Astellas Pharma Inc.

² Professor, School of Pharmaceutical Sciences, University of Shizuoka

³ Associate Professor, Pharmaceutical Science, Kyushu University, Japan

⁴ Associate Professor, Engineering, Kobe University, Japan

* Corresponding author E-mail: hiroyuki.kojima@astellas.com

ABSTRACT

The author presents the history and future prospects of pharmaceutical development from an industry perspective. In the 1980s, there was a strong focus on basic research and evaluations such as absorption from GI tracts, physical properties, drug dissolution. Since the 1990s, not only conventional oral solid dosage forms such as tablet and capsules but also novel pharmaceutical technologies aiming for product value maximization have been extensively investigated. For instance, we firstly developed a medicine with oral disintegrating tablet (ODT) technology in Japan in 1997. That was a point of innovation because the ODT has become one of the major dosage forms nowadays in Japan. In addition to pediatric formulation, the industry has emphasized on drug product development of high-potent compounds when focus has been placed for anticancer drug development since the 2010s. Recently, sterile preparations including antibodies and ADCs (antibody-drug conjugates) as well as drug development of various new modalities including cells and genes are the noteworthy areas of the technology. The author introduces our, RICEP (Reconstitute and Inject CELL Product) technology, a new format of cell product. We developed an approach to manufacture and store the cell drug products, followed by transport under cryogenic conditions. This will allow us the batch production and the storage of cell products for up to several years. It is expected that cost reduction as well as complicated supply chain scheme to arrange the manufacturing/shipment to the date of administration for each patient will be alleviated by thawing and reconstituting the RICEP formulation at the clinical site just before the treatment.

Lipid-Based Novel Formulations for Effective Ocular Drug Delivery

*¹Bhupendra G. Prajapati**

¹ College of Pharmaceutical Education and Research, Ganpat University India

* Corresponding author E-mail: bhupen27@gmail.com

ABSTRACT

Ocular drug delivery remains a significant challenge due to the eye's unique anatomical and physiological barriers, including tear turnover, blinking, and limited permeability of the corneal epithelium. Lipid-based novel formulations have emerged as promising strategies to overcome these obstacles and enhance ocular bioavailability. These systems—such as liposomes, nanoemulsions, solid lipid nanoparticles (SLNs), and nanostructured lipid carriers (NLCs)—offer several advantages, including improved drug solubility, sustained release, mucoadhesion, and protection of labile drugs from degradation. Their biocompatibility and ability to encapsulate both hydrophilic and lipophilic drugs make them ideal candidates for ocular applications. Liposomes mimic biological membranes and enhance corneal penetration, while SLNs and NLCs provide controlled drug release and prolonged retention in the ocular tissues. Moreover, these formulations can be tailored for targeted delivery, reducing systemic absorption and minimizing side effects. Recent advancements in surface modification and mucoadhesive agents further improve the residence time and therapeutic efficacy of lipid-based ocular formulations. Despite some formulation challenges, such as particle stability and sterilization, ongoing research and technological progress continue to drive their development. Overall, lipid-based systems represent a versatile and effective approach to ocular drug delivery, holding significant promise for treating various anterior and posterior segment eye diseases with improved therapeutic outcomes.

Advancing the development of GLP-1 receptor agonist: PK/PD considerations

¹Soyoung Shin*

¹ College of Pharmacy, Chung-Ang University

* Corresponding author E-mail: shins@cau.ac.kr

ABSTRACT

The development of glucagon-like peptide 1 (GLP-1) receptor agonists has significantly advanced the therapeutic landscape for type 2 diabetes and obesity. However, their clinical translation remains challenging due to complex pharmacokinetic (PK) behaviors. We employed highly sensitive and robust LC-MS/MS methods to accurately quantify their concentrations in biological matrices, enabling comprehensive PK characterization. Using these LC-MS/MS methods, the pharmacokinetics of GLP-1 receptor agonists, including liraglutide, semaglutide, and tirzepatide, were comparatively evaluated. To better understand and predict the in vivo pharmacokinetics of these agents, advanced PK modeling strategies, including target-mediated drug disposition (TMDD) and in vitro-in vivo correlation (IVIVC) models, were developed. The TMDD model successfully characterized the dose-dependent nonlinear PK behavior of these peptides. We also employed an IVIVC modeling framework integrated with design of experiment (DoE) to develop sustained-release formulations of GLP-1 receptor agonists. Collectively, our approach highlights the utility of mechanistic PK modeling to overcome challenges associated with peptide therapeutics and accelerate the development of next-generation GLP-1 receptor agonists.

Keywords: GLP-1, LC-MS/MS, Pharmacokinetics, Pharmacodynamics, Target-mediated drug disposition

Venue



Address

Ambassador Hotel Bangkok

171 Sukhumvit Soi 11, Sukhumvit Road, Klongtoey Nue,

Wattana, Bangkok, 10110, Thailand

Website : <https://www.ambassadorbkk.com/>

Tel : +66 2 254 0444

Sponsors / Acknowledgement



We are deeply grateful to the Dr. Kasem Foundation for their unwavering support of the PST conference since 2018, extending through to 2025



Buchi (Thailand) Co., Ltd.

Scion Associated Part., Ltd.

Nine Natural Trading Co., Ltd.

Absotec Co., Ltd.

Sithiphorn Associates Co.,Ltd.

Hollywood International Ltd.

CG Scientific Co., Ltd.

Eirich (Thailand) Co., Ltd.

Applied Chemical and Instrumentation Co., Ltd.

IKA Works (Thailand) Co. Ltd.

Analytical Lab Science Co., Ltd.

Anton Par (Thailand) Co., Ltd.

Lab Leader Co., Ltd.

MEGGLE Singapore Pte Ltd.

Thai Meochems Co., Ltd.

Gene Plus Co., Ltd.

VWR Singapore Pte Ltd.

Bara Scientific Co., Ltd.

CPHI Southeast Asia

VNU Exhibitions Asia Pacific Co., Ltd.

Innovative Instruments Co., Ltd.

ImageProVision Inc.

Mettler-Toledo (Thailand) Ltd.

